Skip to main content
Terug
Watch Compare

TEVA PHARMACEUTICAL INDUSTRIES LTD

Datakwaliteit: 100%
TEVJF
NYSE Manufacturing Chemicals
€ 37,00
▲ € 8,64 (30,47%)
Marktkapitalisatie: 44,72 B
Prijs
€ 37,00
Marktkapitalisatie
44,72 B
Dagbereik
€ 37,00 — € 37,00
52-Weeksbereik
€ 13,73 — € 37,00
Volume
17
Openen € 37,00
50D / 200D Gem.
€ 28,45
30,05% above
50D / 200D Gem.
€ 22,45
64,85% above

Quick Summary

Belangrijkste Punten

Revenue declined -44,56% annually over 5 years
ROE of 20,03% indicates high profitability
Net margin of 94,00% shows strong profitability
Generating 1,65 B in free cash flow
P/E of 31,71 — premium valuation
PEG of 0,89 suggests growth is underpriced

Groei

Revenue Growth (5Y)
-44,56%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)-90,93%
Earnings (1Y)N/A
FCF Growth (3Y)9,79%

Kwaliteit

Return on Equity
20,03%
Boven sectorgemiddelde (-53,47%)
ROIC7,62%
Net Margin94,00%
Op. Margin143,80%

Veiligheid

Debt / Equity
N/A
Current Ratio1,11
Interest Coverage2,35

Waardering

PE (TTM)
31,71
Boven sectorgemiddelde (-1,48)
P/B Ratio6,17
EV/EBITDA13,46
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E 31,7 -1,5
P/B 6,2 1,6
ROE % 20,0 -53,5
Net Margin % 94,0 -41,5
Rev Growth 5Y % -44,6 1,8
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 — 17,14 B —
FY2026 — 16,53 B —

ETFs Holding This Stock

MXIVX MXIVX
0,34% weight
MXJVX MXJVX
0,34% weight
MXECX MXECX
0,11% weight
MXEVX MXEVX
0,11% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -90,93% Revenue Growth (3Y) -69,23%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -44,56% Earnings Growth (5Y) 35,60%
Profitability
Revenue (TTM) 1,50 B Net Income (TTM) 1,41 B
ROE 20,03% ROA 3,53%
Gross Margin 595,87% Operating Margin 143,80%
Net Margin 94,00% Free Cash Flow (TTM) 1,65 B
ROIC 7,62% FCF Growth (3Y) 9,79%
Safety
Debt / Equity N/A Current Ratio 1,11
Interest Coverage 2,35 Asset Turnover 0,04
Working Capital 1,25 B Tangible Book Value -12,63 B
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 31,71 Forward P/E N/A
P/B Ratio 6,17 P/S Ratio 29,81
PEG Ratio 0,89 Forward PEG N/A
EV/EBITDA 13,46 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 3,69%
Market Cap 44,72 B Enterprise Value 42,51 B
Per Share
EPS (Diluted TTM) 1,21 Revenue / Share 1,24
FCF / Share 1,36 OCF / Share 1,36
EPS CAGR (1Y) N/A EPS CAGR (5Y) 33,58%
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 116,95%
SBC-Adj. FCF 1,51 B Growth Momentum -46,37

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,50 B 16,54 B 15,85 B 14,93 B 15,88 B
Net Income 1,41 B -1,64 B -559,00 M -2,35 B 417,00 M
EPS (Diluted) 1,21 -1,45 -0,50 -2,12 0,38
Gross Profit 8,94 B 8,06 B 7,65 B 6,97 B 7,59 B
Operating Income 2,16 B -303,00 M 433,00 M -2,10 B 1,72 B
EBITDA — — — — —
R&D Expenses — — — 98,00 M —
SG&A Expenses — — — — —
D&A 1,00 B 1,06 B 1,15 B 1,31 B 1,33 B
Interest Expense 916,00 M 1,00 B 1,03 B 930,00 M 891,00 M
Income Tax -180,00 M 676,00 M -7,00 M -638,00 M 211,00 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 40,75 B 39,33 B 43,48 B 44,01 B 47,67 B
Total Liabilities 32,83 B 33,61 B 35,35 B 35,32 B 36,42 B
Shareholders' Equity 7,91 B 5,37 B 7,51 B 7,90 B 10,28 B
Total Debt — — — — —
Cash & Equivalents 3,56 B 3,30 B 3,23 B 2,80 B 2,17 B
Current Assets 13,95 B 12,55 B 12,49 B 12,05 B 12,57 B
Current Liabilities 13,46 B 12,80 B 12,25 B 11,47 B 11,03 B